Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

PRWeb
admin
This post was originally published on this site

– Acthar Gel Single-Dose Pre-filled SelfJect Injector is a self-controlled, pre-filled delivery device1 for appropriate patients with a range of chronic and acute inflammatory and autoimmune conditions2 – – This first-in-class delivery device reduces the steps required for patients and…

Related Posts

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

admin

Greenberg Traurig’s Philip Person Participates in CEB Webinar on…

admin

United Way Suncoast implements StratusLIVE’s Nonprofit Industry Cloud Solution for digital engagement and donor management

admin